Related Experiment Video

Updated: Jul 9, 2025

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.6K

Myelitis as a side effect of tofersen therapy in SOD1-associated ALS

Peter Reilich1,2, Florian Schöberl3, Miriam Hiebeler4

  • 1Friedrich Baur Institute at the Department of Neurology, University Hospital, LMU Munich, Ziemssenstr. 1, 80336, Munich, Germany. Peter.Reilich@med.uni-muenchen.de.

Journal of Neurology
|December 8, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.7K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.1K

Related Experiment Videos

Last Updated: Jul 9, 2025

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.6K
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.7K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.1K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K

Articles linked to this work by shared authors, journal, and citation graph.

Analysis and occurrence of biallelic pathogenic repeat expansions in RFC1 in a German cohort of patients with a main clinical phenotype of motor neuron disease.

Journal of neurology·2024

Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease.

Biomedicines·2022

CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer's disease.

Journal of neurology, neurosurgery, and psychiatry·2022

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy.

Annals of clinical and translational neurology·2022

Fast versus slow disease progression in amyotrophic lateral sclerosis-clinical and genetic factors at the edges of the survival spectrum.

Neurobiology of aging·2022

Increased pyroptosis activation in white matter microglia is associated with neuronal loss in ALS motor cortex.

Acta neuropathologica·2022

Medication use trajectories in myasthenia gravis pregnancies: a population-based drug utilization study.

Journal of neurology·2026

Adjunctive corticosteroids in herpes simplex virus encephalitis: a meta-analysis of randomized and observational studies.

Journal of neurology·2026

Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review.

Journal of neurology·2026

GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes.

Journal of neurology·2026

Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial.

Journal of neurology·2026

A comparison study of thymectomy outcomes in young and older patients with non-thymomatous myasthenia gravis.

Journal of neurology·2026

Radiocopper in BCMA-targeted immunotheranostics of myeloma.

Theranostics·2026

hNET-targeted [18F]MFBG PET as baseline functional imaging in newly diagnosed neuroblastoma.

Theranostics·2026

Nano-flow intracalvariosseous infusion enables skull-to-brain delivery of BBB-impermeable molecular and nanoscale agents in mice and rabbits.

Theranostics·2026

Design of a Pragmatic Randomized Controlled Trial for Comparing the Michigan Screening and Intervention for Glaucoma and Eye Health and Telemedicine Protocol with Usual Care for Disease Detection.

Clinical ophthalmology (Auckland, N.Z.)·2026

Erratum: Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy: Erratum.

Theranostics·2026

Correction: Editorial: Advancements in meningioma management: from imaging techniques to personalized medicine approaches.

Frontiers in neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us